Oxidopamine - Pharmacology
Research News and Information

Sunday, November 22, 2009

CIB1 functions as a Ca(2+)-sensitive modulator of stress-induced signaling by targeting ASK1.

27 Sep 2009 Calcium and integrin binding protein 1 (CIB1) is a Ca(2+)-binding protein of 22 kDa that was initially identified as a protein that interacts with integrin alpha(IIb). Although it interacts with various proteins and has been implicated in diverse ... Read more...

The role of the neural sympathetic and parasympathetic systems in diurnal and sleep state-related cardiovascular rhythms in the late-gestation ovine fetus.

27 Jul 2009 The efferent mechanisms mediating the well-known diurnal cardiovascular rhythms in the late-gestation fetus are only partially understood. In the present study, we evaluated the contribution of the parasympathetic and sympathetic nervous systems ... Read more...

Neural cell protective compounds isolated from Phoenix hanceana var. formosana.

19 Jul 2009 A platform for screening drugs for their ability to protect neuronal cells against cytotoxicity was developed. Nerve growth factor (NGF) differentiates PC12 cells into nerves, and these differentiated PC12 cells enter apoptosis when challenged with ... Read more...

Latest indexed articles for 'Oxidopamine - Pharmacology'

These are the very latest articles for this heading:

• CIB1 functions as a Ca(2+)-sensitive modulator of stress-induced signaling by targeting ASK1. 27 Sep 2009
• The role of the neural sympathetic and parasympathetic systems in diurnal and sleep state-related cardiovascular rhythms in the late-gestation ovine fetus. 27 Jul 2009
• Neural cell protective compounds isolated from Phoenix hanceana var. formosana. 19 Jul 2009
• Dopamine-deprived striatal GABAergic interneurons burst and generate repetitive gigantic IPSCs in medium spiny neurons. 15 Jun 2009
• Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior. 6 Jun 2009
• Not lost in translation Sensing the loss and filling the gap during regeneration. 18 May 2009
• Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: potential effects in a 6-OHDA-induced model of Parkinson's disease. 29 Apr 2009
• Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat. 17 Apr 2009
• Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. 18 Mar 2009
• Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum. 11 Mar 2009
• Sympathetic nervous system control of anti-influenza CD8+ T cell responses. 11 Mar 2009
• Single administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline increases the extracellular concentration of dopamine in rat striatum. 10 Mar 2009
• Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. 13 Feb 2009
• [Research progress on pharmacological activities of echinacoside] 30 Jan 2009
• RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. 29 Dec 2008
• Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis. 8 Dec 2008
• Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. 5 Nov 2008
• JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. 3 Nov 2008
• Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. 30 Oct 2008
• Natural and lesion-induced apoptosis in the rat striatum during development. 26 Oct 2008

See a longer list of these articles.

Technical information about 'Oxidopamine'

Definition: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.

Chemical name: 1,2,4-Benzenetriol, 5-(2-aminoethyl)-

Registry Number: 1199-18-4

Descriptor UI: D016627

Alternative terms: Oxidopamine; 6-OHDA; 6-Hydroxydopamine; 6 Hydroxydopamine; Oxidopamine Hydrochloride; Hydrochloride, Oxidopamine; Oxidopamine Hydrobromide; Hydrobromide, Oxidopamine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Sympatholytics; Adrenergic Agents;

Tree Number: D02.092.311.342.478.650;

Online Note: use OXIDOPAMINE (NM) to search 6-HYDROXYDOPAMINE (NM) 1980-91

History Note: 92; was 6-HYDROXYDOPAMINE (NM) 1981-91